trending Market Intelligence /marketintelligence/en/news-insights/trending/65wb43_efPZxvuGBXEy1gA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Daré Bioscience's vaginal infection gel gets US FDA infectious disease status

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Daré Bioscience's vaginal infection gel gets US FDA infectious disease status

The U.S. Food and Drug Administration granted qualified infectious disease product status to Daré Bioscience Inc.'s antibacterial gel for vaginal infections.

San Diego, Calif-based Daré is developing DARE-BV1, a thermosetting hydrogel containing clindamycin phosphate 2%, to treat bacterial vaginosis a common infection caused by the overgrowth of bacteria naturally found in the vagina.

DARE-BV1 is a viscous liquid designed to undergo solution to gel transition using body temperature as the trigger, which allows the product to be more easily directed to the site of infection.

The approval was based on the company's proof-of-concept study, which showed that 86% of patients with bacterial vaginosis had no signs or symptoms of the disease after 7 to 14 days following a single administration of DARE-BV1.

Daré plans to initiate a phase 3 study of DARE-BV1 in about 250 women in the fourth quarter of 2019. Daré Bioscience said the phase 3 study is expected to be sufficient to secure an approval for DARE-BV1 as a treatment for bacterial vaginosis, based on the company's discussion with the FDA.

Qualified infectious disease designation is granted to drug candidates that treat serious infections, particularly those caused by bacteria and fungi that are resistant to treatment. The status allows for certain incentives to develop the therapies.